Trials / Completed
CompletedNCT02391480
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or combination therapy in disease specific expansion cohorts.
Conditions
- Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
- Acute Myeloid Leukemia (AML)
- Multiple Myeloma
- Prostate Cancer
- Small Cell Lung Cancer
- Non-Hodgkins Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-075 | ABBV-075 Oral tablets |
| DRUG | Venetoclax | Venetoclax tablets, film-coated |
Timeline
- Start date
- 2015-04-14
- Primary completion
- 2019-07-05
- Completion
- 2019-07-05
- First posted
- 2015-03-18
- Last updated
- 2019-11-29
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02391480. Inclusion in this directory is not an endorsement.